Skip to main content

Table 5 Probabilsitic parameters

From: Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada

Variable Mean Value Distribution (parameters) 95% C.I. based on parameters
IVIG Response Rate 0.473 beta (α = 35.52,β = 39.61) (0.361, 0.585)
IVIG relapse rate (25 weeks) 0.13 beta (α = 4.03, β = 26.97) (0.039, 0.266)
IVIG incremental utility 0.12 normal (μ = 0.12,β = 0.08) (-0.05, 0.29)
Corticosteroid adverse events annual probailites    
   Fracture 0.0098 beta (α = 1.20,β = 120.8) (0.000,0.033)
   Diabetes mellitus 0.0043 beta (α = 0.48,β = 111.52) (0.000,0.022)
   Cataract 0.0114 beta (α = 1.39,β = 120.61) (0.001,0.036)
   Glaucoma 0.0008 beta (α = 0.09,β = 111.91) (0.000,0.008)
   Serious Infection 0.0035 beta (α = 0.39,β = 120.8) (0.000,0.020)
Glaucoma utility weight 0.96 beta (α = 214.32, β = 13.68) (0.906,0.967)
Cataract utility weight-before surgery 0.62 beta (α = 62, β = 38) (0.586,0.767)
Cataract utility weight post-surgery 0.90 beta (α = 90, β = 10) (0.835,0.951)
Glaucoma utility weight 0.96 beta (α = 214.32, β = 13.68) (0.906,0.967)